MSD Animal Health Receives Marketing Authorization From European Commission for BRAVECTO (fluralaner)
2/17/2014 8:38:38 AM
SUMMIT, N.J.--(BUSINESS WIRE)--MSD Animal Health, known as Merck Animal Health in the United States and Canada, announced today that following a positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP), the European Commission has granted marketing authorization for the veterinary medicinal product BRAVECTO™ (fluralaner) chewable tablets for dogs (112.5 mg, 250 mg, 500 mg, 1000 mg, 1400 mg). This is the first and only treatment that has been shown to quickly and effectively kill fleas and ticks for up to 12 weeks in a single dose.*
Help employers find you! Check out all the jobs and post your resume.
comments powered by